MarketPulse
A

$ACIU

2 articles found
2 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Ac Immune Sa

AC Immune's TDP-43 Tracer Shows Promise in ALS Patients, Expanding to FTD Trial

AC Immune's ACI-19626 PET tracer demonstrates superior uptake in ALS patients versus controls, with positive safety data advancing Phase 1b expansion to neurodegeneration study.
ACIUALSneurodegenerative diseases
GlobeNewswire Inc.GlobeNewswire Inc.··Ac Immune Sa

AC Immune, Lilly Expand Tau Partnership With $11M Upfront as Alzheimer's Race Heats Up

AC Immune and Eli Lilly amend collaboration to advance tau-targeting Alzheimer's candidates, with $11M upfront and IND studies starting mid-2026.
LLYACIUneurodegenerative diseasesAlzheimer's disease